Rosalind Advisors, Inc.
Clone Performance
Feb 2024–Aug 2026 · vs SPYHypothetical growth of buying every stock this filer reported holding, rebalancing on each filing and indexed to the same start. Option positions cannot be bought this way and are left out.
Estimate. 13F holdings are quarter-lagged, so the clone rebalances about 45 days after each period end — when the filing becomes public — and it excludes option and short positions. Returns use comparable raw closes and exclude dividends; a captured split can shorten the simulated window. It tracks 100% of reported value on average across 11 quarters. Past performance does not predict future results.
Portfolio Concentration
29 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $266,977,310 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| VSTM | Verastem, Inc. | +1,848,034 | 3,986,509 | $15,228,464 | |
| TLPH | Talphera, Inc. | +1,815,585 | 5,169,501 | $5,324,586 | |
| RGNT | Regentis Biomaterials Ltd. | +450,175 | 701,685 | $2,476,948 | |
| HELP | Cybin Inc. | +425,000 | 1,956,814 | $12,934,540 | |
| FENC | Fennec Pharmaceuticals Inc. | +279,800 | 3,188,001 | $34,271,010 | |
| NRXS | Neuraxis, INC | +221,917 | 508,055 | $3,713,882 | |
| BFRI | Biofrontera Inc. | +111,647 | 1,275,609 | $1,206,726 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| XERS | Xeris Biopharma Holdings, Inc. | −322,719 | 2,908,981 | $23,039,129 | |
| OKUR | OnKure Therapeutics, Inc. | −293,763 | 150,000 | $684,000 | |
| MYO | Myomo, Inc. | −209,386 | 3,637,886 | $3,783,401 | |
| PYPD | PolyPid Ltd. | −208,471 | 389,455 | $1,978,431 | |
| BCRX | Biocryst Pharmaceuticals Inc | −201,553 | 721,504 | $7,215,040 | |
| CLDX | Celldex Therapeutics, Inc. | −130,000 | 200,000 | $7,442,000 | |
| AVIR | Atea Pharmaceuticals, Inc. | −101,305 | 1,070,550 | $4,978,057 | |
| PCVX | Vaxcyte, Inc. | −90,000 | 200,000 | $11,626,000 | |
| VOR | Vor Biopharma Inc. | −51,400 | 648,600 | $11,940,726 | |
| EYPT | EyePoint, Inc. | −48,507 | 988,230 | $14,131,689 | |
| SVRA | Savara Inc | −25,600 | 3,178,121 | $19,577,225 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 100,000 | $6,768,000 | |
| VRDN | Viridian Therapeutics, Inc.\DE | 250,401 | $4,897,843 | |
| DFTX | Definium Therapeutics, Inc. | 125,000 | $2,362,500 | |
| LPCN | Lipocine Inc. | 221,616 | $1,770,711 | |
| AVTX | Avalo Therapeutics, Inc. | 75,000 | $1,119,750 | |
| ANNX | Annexon, Inc. | 200,000 | $1,108,000 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| DCTH |
Delcath Systems, Inc.
Healthcare
|
Held | 3,300,389 | $41,551,897 | 15.56% | |
| FENC |
Fennec Pharmaceuticals Inc.
Healthcare
|
Reduced | 3,188,001 | $34,271,010 | 12.84% | |
| XERS |
Xeris Biopharma Holdings, Inc.
Healthcare
|
Reduced | 2,908,981 | $23,039,129 | 8.63% | |
| SVRA |
Savara Inc
Healthcare
|
Reduced | 3,178,121 | $19,577,225 | 7.33% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Added | 3,986,509 | $15,228,464 | 5.70% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Held | 3,214,766 | $15,012,957 | 5.62% | |
| EYPT |
EyePoint, Inc.
Healthcare
|
Reduced | 988,230 | $14,131,689 | 5.29% | |
| HELP |
Cybin Inc.
Healthcare
|
Added | 1,956,814 | $12,934,540 | 4.84% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Reduced | 648,600 | $11,940,726 | 4.47% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Reduced | 200,000 | $11,626,000 | 4.35% | |
| MDWD |
MediWound Ltd.
Healthcare
|
Held | 749,054 | $11,011,093 | 4.12% | |
| CLDX |
Celldex Therapeutics, Inc.
Healthcare
|
Reduced | 200,000 | $7,442,000 | 2.79% | |
| BCRX |
Biocryst Pharmaceuticals Inc
Healthcare
|
Reduced | 721,504 | $7,215,040 | 2.70% | |
| PROF |
Profound Medical Corp.
Healthcare
|
Held | 828,118 | $5,506,984 | 2.06% | |
| TLPH |
Talphera, Inc.
Healthcare
|
Added | 5,169,501 | $5,324,586 | 1.99% | |
| AVIR |
Atea Pharmaceuticals, Inc.
Healthcare
|
Reduced | 1,070,550 | $4,978,057 | 1.86% | |
| MYO |
Myomo, Inc.
Healthcare
|
Reduced | 3,637,886 | $3,783,401 | 1.42% | |
| NRXS |
Neuraxis, INC
Healthcare
|
Added | 508,055 | $3,713,882 | 1.39% | |
| OVID |
Ovid Therapeutics Inc.
Healthcare
|
Held | 1,107,994 | $2,980,503 | 1.12% | |
| ABVX |
Abivax S.A.
Healthcare
|
NEW | 20,869 | $2,781,002 | 1.04% | |
| NSPR |
InspireMD, Inc.
Healthcare
|
Held | 3,905,743 | $2,734,020 | 1.02% | |
| RGNT |
Regentis Biomaterials Ltd.
Healthcare
|
Added | 701,685 | $2,476,948 | 0.93% | |
| PYPD |
PolyPid Ltd.
Healthcare
|
Reduced | 389,455 | $1,978,431 | 0.74% | |
| BFRI |
Biofrontera Inc.
Healthcare
|
Added | 1,275,609 | $1,206,726 | 0.45% | |
| KURA |
Kura Oncology, Inc.
Healthcare
|
Held | 100,000 | $1,097,000 | 0.41% | |
| SPRB |
Spruce Biosciences, Inc.
Healthcare
|
NEW | 20,000 | $1,080,000 | 0.40% | |
| AQST |
Aquestive Therapeutics, Inc.
Healthcare
|
Held | 250,000 | $1,040,000 | 0.39% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Reduced | 150,000 | $684,000 | 0.26% | |
| PEPG |
PepGen Inc.
Healthcare
|
NEW | 350,000 | $630,000 | 0.24% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.